Lupus Nephritis (LN) Clinical Trials

14 recruiting

Lupus Nephritis (LN) Trials at a Glance

14 actively recruiting trials for lupus nephritis (ln) are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 1 with 7 trials, with the heaviest enrollment activity in Nanjing, Beijing, and Beijing. Lead sponsors running lupus nephritis (ln) studies include China Immunotech (Beijing) Biotechnology Co., Ltd., First Affiliated Hospital, Sun Yat-Sen University, and Beijing GoBroad Hospital.

Browse lupus nephritis (ln) trials by phase

Treatments under study

About Lupus Nephritis (LN) Clinical Trials

Looking for clinical trials for Lupus Nephritis (LN)? There are currently 14 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lupus Nephritis (LN) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lupus Nephritis (LN) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 114 of 14 trials

Recruiting
Phase 1

Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis

Lupus Nephritis (LN)
Regeneron Pharmaceuticals90 enrolled11 locationsNCT06975787
Recruiting
Phase 1

A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)

Lupus Nephritis (LN)Systemic Lupus Erthematosus (SLE)Extra-renal Lupus (ERL)
Hinge Bio30 enrolled1 locationNCT07491900
Recruiting
Phase 2

The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)
Nanjing University School of Medicine50 enrolled1 locationNCT07340463
Recruiting
Phase 1Phase 2

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)
Beijing GoBroad Hospital18 enrolled1 locationNCT06585514
Recruiting
Phase 1

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus ErythematosusLupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07236762
Recruiting
Phase 1

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07104721
Recruiting
Phase 1

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Sjogren's Syndrome (SS)+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07123519
Recruiting

Research Accelerated by You Lupus Registry

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Cutaneous Lupus Erythematosus (CLE)
Lupus Foundation of America10,000 enrolled1 locationNCT06927219
Recruiting
Phase 2

Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN

Lupus Nephritis (LN)
Haisco Pharmaceutical Group Co., Ltd.105 enrolled1 locationNCT07363460
Recruiting
Early Phase 1

Safety and Efficacy of ONT01 in Lupus

Systemic Lupus ErythematosusSLELupus Nephritis (LN)+5 more
Hospital for Special Surgery, New York61 enrolled1 locationNCT07107659
Recruiting
Phase 2

A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis

Lupus Nephritis (LN)Membranous Nephropathy
Shanghai Henlius Biotech24 enrolled17 locationsNCT07038382
Recruiting
Phase 1

A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus

Lupus Nephritis (LN)Immune Thrombocytopenia (ITP)
China Immunotech (Beijing) Biotechnology Co., Ltd.36 enrolled1 locationNCT06943937
Recruiting
Not Applicable

Equecabtagene Autoleucel Injection (Eque-cel) for Relapsed/Refractory Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)
Tongji Hospital6 enrolled1 locationNCT06902844
Recruiting

High Quality Evidence of Guangzhou Lupus Nephritis Cohort (HOPE Cohort)

Lupus Nephritis (LN)
First Affiliated Hospital, Sun Yat-Sen University5,000 enrolled1 locationNCT06682507